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Abstract
An affinity chromatography strategy was used to search for proteins in A549 cells which interact with the N-terminus of
 .lipocortin 1 annexin 1 . Using the biologically active fragment Lc13–25 as the affinity ligand, two proteins of molecular
 .weight m.w. 52 and 48 kDa were extracted. Affinity blots of these proteins bound iodinated Lc13–25. Partial tryptic
digests of these proteins were analysed by matrix assisted laser desorption mass spectrometry and found to display
fragmentation patterns with a strong similarity to those of cytokeratin 8 and 18 respectively. Subsequent blotting with a
panel of specific cytokeratin antibodies strongly supported the idea that the two proteins were cytokeratin 8 and cytokeratin
 .18. Cytokeratin 8 was isolated from A549 cells in intermediate filament IF preparations which were also found to contain
 .lipocortin 1 as a potential intermediate filament associated protein IFAP . This association persisted throughout cycles of IF
assembly and disassembly. Dual-labelling immuno-histochemistry in A549 cells showed strong co-localization of lipocortin
1 and cytokeratin 8. The implications of this finding are discussed in the light of the biological activity and possible
function of lipocortin 1. q 1998 Published by Elsevier Science B.V.
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1. Introduction
 .Lipocortin 1 also called annexin 1 is a 37 kDa
protein whose synthesis and cellular disposition is
controlled by glucocorticoids and which has been
implicated in many glucocorticoid actions including
) Corresponding author. Fax: 0171-982-6085; E-mail:
j.croxtall@qmw.ac.uk
inhibition of cell growth, inflammation, fever, cell
differentiation, exocytosis, ion channel function and
w xregulation of HPA axis function 1,2 .
The family of annexin proteins is characterized by
a core domain 4 unit repeat structure common to each
w xprotein 3 . This domain mediates binding of the
protein to phospholipid structures in a Ca2q-depen-
w xdent manner 3 . Each annexin is however distin-
guished by a unique N-terminal domain of variable
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w xsize 3 . In some circumstances this domain mediates
binding to other proteins which can occur in the
2q w xabsence of Ca 4 . The inhibitory activity of
lipocortin 1 has been largely attributed to the phos-
pholipid binding core domain by virtue of its ability
w xto sequester the substrate of PLA 5 . However, the2
demonstration of extracellular, protease-sensitive, sat-
urable binding sites in several cell types indicates the
w xpossibility of another type of interaction 6,7 . Fur-
thermore, we have shown that peptide fragments
derived from the N-terminal domain mimic the activ-
w xity of the parent protein 8–10 . This implies that an
association with key target proteins, at least some of
which are on the surface of the cell, is also a feature
of lipocortin 1 action.
To search for possible candidate proteins we have
devised an affinity chromatography strategy using
A549 cells which exhibit lipocortin 1 induction in
w xresponse to glucocorticoids 11,12 , as a prospective
 .source of binding protein s . The most active peptide
sequence derived from lipocortin 1 is the fragment
Lc13–25 which inhibits cell growth and the release
w xof arachidonic acid from A549 cells 8,9 . We have
therefore used Lc13–25 as an affinity ligand with
which to search for putative candidate binding pro-
teins with the object of increasing our understanding
of the mechanisms whereby lipocortin 1 produces its
biological effects. We now report that two major
binding proteins have been isolated and that these
have been identified and confirmed by physio-
chemical and immunological methods to be cytoker-
atins 8 and 18.
2. Materials and methods
A549 cells were obtained from ICN-Flow and
routinely checked for the absence of mycoplasma
contamination. Dulbecco’s modified Eagle’s
 .mediumrF12 DMEMrF12 and fetal calf serum
 . XFCS were from Sigma. 1,1-carbonyldiimidazole ac-
 .tivated cross-linked 6% agarose Reacti-Gel 6X and
Iodo-beads were from Pierce and Warriner, Chester,
 .UK. The peptides Lc13–25 FIENEEQEYVQTV
 .and Lc1–12 MAMVSEKLKQAW were kindly pre-
pared by Dr Gerd Schnorrenberg, Boehringer Ingel-
125  .heim KG. Iodine 100 mCirml was from Amer-
sham. Western blotting was performed with the fol-
lowing monoclonal antibodies against human cytok-
 .eratins from Sigma: Cytokeratin 4 6B10 , cytoker-
 .  .atin 8 M20 , cytokeratin 17 CKE3 , cytokeratin 18
 .  .CY-90 , cytokeratin 19 K4.62 and A53 and a
 .pan-specific cytokeratin antibody clone no. C11 .
The monoclonal anti-cytokeratin 8 used for immuno-
histochemistry was from Monosan, The Netherlands.
The sheep anti-lipocortin 1 antibody was raised in
house using human recombinant lipocortin 1 as anti-
gen. FITC-conjugated rabbit anti-sheep IgG was from
Zymed Laboratories, USA and Rhodamine-con-
jugated rabbit anti-mouse IgGrIgM was from Jack-
son Immunological Research Laboratories, USA. All
other reagents were from Sigma, UK, unless stated
otherwise.
2.1. A549 cell culture
A549 cells were maintained in T150 flasks
 .Greiner in continuous log-phase growth in
DMEMrF-12, 10% FCS. Following washing with
PBS, 1 mM EDTA, cells were harvested at sub-con-
 6 .fluence approximately 20=10 per flask by lysing
in 1.5 ml PBS, 10 mM EDTA, 1% Triton X-100,
1 mM PMSF, 0.001% leupeptin. Usually 20 T150
flasks were used for each affinity preparation.
2.2. Affinity purification
 .25 mg of the peptide Lc13–25 or Lc1–12 was
immobilized by cross-linking in 10 ml of Reacti-Gel
slurry in a coupling buffer of 0.1 M NaHCO , pH103
at 48C with continuous stirring for 18 h. Remaining
cross-linking sites were blocked with 0.2 M glycine,
pH 8.0 for 2 h and the slurry washed with excess
coupling buffer followed by 5 volumes of H O.2
A549 cell lysates from 20 T150 flasks were pooled
 .approximately 30 ml and the Lc13–25 bound slurry
added with continuous stirring at 48C for 18 h. The
slurry was washed with 5 volumes of 20 mM Tris,
 .2 mM EDTA, pH 8.0 which was retained and
specifically bound proteins eluted in 20 ml 0.1 M
HCl, pH 2.0. Eluted protein was precipitated by
adding ice cold TCA to the eluate to a final concen-
tration of 10% for 2 h followed by centrifugation at
10 000=g for 20 min at 48C.
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2.3. Iodination of Lc13–25
125  .1 mCi of I 10 ml was incubated with one
Iodo-bead in 180 ml 100 mM phosphate buffer, pH
6.5 for 5 min. 100 mg of Lc13–25 in 10 ml phosphate
buffer, pH 6.5 was then added for a further 5 min.
Labelled peptide was separated from free 125I using a
 .  .G-10 sephadex Sigma column 10 ml bed volume
and 1.5 ml fractions collected. The fractions contain-
ing the labelled peptide were pooled. The specific
activity of the product was approximately 1 mCirmg.
2.4. Electrophoresis and western blotting
Total A549 cell lysate, unbound wash through and
eluted proteins were analysed by SDS–PAGE on
20=20 cm gels using 10% acrylamide. The gels
were run in parallel, and either stained with PAGE
 .Blue 250 Sigma , or transferred to PVDF membrane
 .Millipore and following blocking with 5% milk fat
powder incubated with 100 mCi 125I-Lc13–25 for
18 h. 10=8 cm mini-gels were used with 10% acryl-
amide for western blotting using either specific anti-
cytokeratin antibodies at the manufacturers recom-
mended dilutions or an in house sheep anti-lipocortin
1 antibody at 1 : 5000. Bands were detected with
HRP-conjugated second antibody and developed with
diaminobenzidine.
2.5. Amino acid sequence analysis
Samples were separated by electrophoresis in
 .ready-made SDS 20% poly-acrylamide gels Daiichi
and transferred to polyvinylidene difluoride mem-
 .  .brane PSQ, Millipore in 10% vrv methanol,
10 mM CAPS, pH 11. Protein bands were stained by
 .a 1 min wash in Ponceau S 0.15% wrv in water ,
destained in water and air dried. The red protein
bands were excised either for protein sequencing
 .using a 470A sequencer ABI with an on-line 190A
analyser, or for proteolysis prior to mass spectromet-
ric analysis.
For proteolysis, blotted samples were destained in
5 mM NaOH then in water and air dried. The sample
pieces were cut into 1 mm2 squares and wetted with
4–6ml of either 8 or 80 mgrml trypsin Promega,
.alkylated sequencing grade in 25 mM NH HCO ,4 3
 .  .10% vrv methanol, 1% wrv octyl glucoside,
5 mM DTT for 18 h at 378C. Combined extracts were
dried under vacuum, redissolved in 4 ml of 10%
methanol and applied to the mass spectrometer. Stan-
 .dard horse myoglobin and blank controls were run
to provide internal markers and assessment of back-
ground.
2.6. Mass spectrometry
 .An aliquot of the extracted digest 0.5 ml was
mixed with 0.5 ml of an internal calibrant substance
.P, 1347.7 Da and 0.5 ml a-cyano-4-hydroxy cinnamic
 .acid 10 mgrml in 70% vrv acetonitrile . The mix-
ture was applied to the target and allowed to air dry
prior to analysis. The mass spectrometer used was a
 .Lasermat 2000 Thermo BioAnalysis, UK . Typically
20–24 single spectra were summed to generate data
for peptide fingerprinting.
Peptide signals between 700 and 2500 Da were
selected from the spectrum and used to search a
tryptic peptide mass database created from a CD-
ROM based sequence database National Centre for
Biotechnology Information, NIH, Bethesda, MD, En-
. trez, version 20.0 using MassMap software Thermo
.BioAnalysis . The search generated a list of proteins
that corresponded to the peptide signals. Each protein
was assigned a score based on the number of peptides
that matched the peptide mass distribution statistics
determined during the creation of the database and
 .the molecular weight m.w. of the protein calculated
from the sequence. From the list of proteins with the
highest scores the original Entrez database files could
be extracted providing additional mass data on pep-
tide fragments for comparison with the spectrum.
2.7. Intermediate filament preparation
 .An intermediate filament IF enriched preparation
was isolated from A549 cell pellets by lysing in PBS
containing 0.6 M KCl, 1% Triton X-100, 10 mM
w xMgCl , 1% mercaptoethanol and 1 mM PMSF 13 .2
The lysate was dispersed by the addition of DNase I
 .Sigma to a final concentration of 0.5 mgrml and
IFs pelleted by centrifugation at 1600=g for 10 min.
The IF pellet was washed three times in PBS, 1%
mercaptoethanol, 1 mM PMSF.
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2.8. Double immunofluoresence
A549 cells were cultured on glass coverslips in
DMEMrF-12, 10% FCS. Cells grown to the desired
density were rinsed in PBS, fixed in methanol at
y208C for 10 min, and air dried. For double-label-
ling immunofluoresence microscopy, each cover slip
was overlaid with a mixture of sheep anti-lipocortin 1
 .raised in house and monoclonal anti-cytokeratin 8
 .Monosan, Netherlands both at 1 : 10 dilutions and
incubated at 378C for 2 h. After incubation, the cover-
slips were washed three times in PBS, and then
incubated with FITC-conjugated rabbit anti-sheep IgG
 .Zymed Laboratories, USA , 1 : 15, and Rhodamine-
conjugated rabbit anti-mouse IgGrIgM Jackson Im-
.munological Research Laboratories, USA , 1 : 30, at
378C for 1 h. After washing twice with PBS and
rinsing with distilled water the coverslips were
 .mounted on glass slides in Fluoromount-G Sigma .
Controls for cross-reactivity between the two sec-
 .ondary antibodies anti-mouse IgG and anti-goat IgG
consisted of incubating the cells on coverslips with
either sheep anti-lipocortin 1 and monoclonal anti-cy-
tokeratin 8, followed by incubation with a mixture of
both secondary antibodies. Cells were examined with
a Zeiss Axiophot microscope equipped with an epi-
fluoresence system.
3. Results
3.1. Affinity purification on immobilized Lc13–25
The lysate of 20 T150 flasks of sub-confluent
 6.A549 cells approximately 400=10 was subjected
to affinity chromatography using peptide Lc13–25
from the N-terminus of lipocortin 1 immobilized on
an agarose matrix. Following extensive washing with
Ca2q-free coupling buffer, specifically bound protein
was eluted with Ca2q-free 0.1 M HCl, precipitated
and subjected to SDS–PAGE. An aliquot of the total
cell lysate and the unbound wash through which had
been concentrated by TCA precipitation was retained
  .and also evaluated by SDS–PAGE Fig. 1 A . Stain-
ing of the low pH eluate with PAGE Blue 250
revealed two prominent bands of m.w. 52 and 48 kDa
  . .Fig. 1 B , arrows . The removal of these proteins
from the total cell lysate is indicated by the corre-
sponding reduction in intensity of the 52 and 48 kDa
  . .bands in the wash through Fig. 1 A , lane 2, arrows .
 .Fig. 1. Affinity purification of cytokeratins 8 and 18 on immobilized Lc13–25. SDS–PAGE stained with PAGE Blue 250 of A total
 .  .  .A549 cell lysate lane 1 and unbound wash through lane 2 and B following elution with 0.1 M HCl two bands of 52 and 48 kDa are
 . 125precipitated. C Parallel SDS–PAGE transferred to PVDF membrane and incubated with 100 mC I-Lc13–25 also reveals two bands of
52 and 48 kDa.
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Several other minor bands of approximately 18–
20 kDa were present in low abundance. Eluted sam-
ples were also run in parallel on a further gel and
transferred to PVDF and, following blocking with 5%
dried milk fat, incubated with 100 mCi 125I-Lc13–25
  ..for 18 h Fig. 1 C . The membrane was washed
 .extensively with PBS, Tween-20 1% and then ex-
posed to Kodak X-OMAT film for 48 h. The devel-
oped film was then aligned with the protein gel to
reveal that the same bands of 52 and 48 kDa were
labelled with the 125I-Lc13–25 fragment. No other
bands were labelled. This demonstrates that these two
protein bands were specifically bound to the peptide
Lc13–25 on the affinity matrix and that following
SDS–PAGE these proteins still retained the capacity
to bind the peptide. The binding of the 52 and 48 kDa
proteins is apparently specific to Lc13–25 as a simi-
lar matrix using Lc1–12 as a ligand failed to recover
 .these proteins data not shown and a scrambled
w xsequence of Lc13–25 is devoid of activity 8–10 .
The sequence of Lc13–25 is derived from the least
hydrophobic portion of the lipocortin 1 N-terminus
and since the purification was performed in Ca2q-free
conditions it is unlikely that the association is medi-
ated by binding phospholipid.
3.2. Identification of protein bands
Samples were run on SDS–PAGE and transferred
to PVDF membrane as above. Membranes were
stained with Ponceau S to identify protein bands and
the main bands excised for N-terminal sequence anal-
ysis. No results were obtained by this method indicat-
ing that the N-terminus was blocked either naturally
or during preparation. So instead, excised bands were
subjected to a controlled digestion with trypsin and
the peptide fragments thus released were extracted
and analysed by matrix assisted laser desorption mass
 .spectrometry MALDI-MS . The 48 kDa band gener-
ated a complex spectrum of peptide signals. Eight
mass fragments were selected for searching in
MassMap. Human cytokeratin 18 was the protein in
the database with the closest match to the observed
 .mass values hits, Table 1 . Six of the mass signals
gave seven hits four full and three partial digest
.peptides in a theoretical digest of cytokeratin 18
 .Table 2 . Further evidence for the positive identifica-
tion of cytokeratin 18 was provided by comparing the
theoretical digest with the complete mass spectrum.
A further sixteen signals corresponded to seven full
and nine partial digest peptides observed in cytoker-
atin 18. Confidence was also gained from the com-
parison of the spectrum of cytokeratin 18 from other
species, such as sheep and mouse, which were also in
the database.
The 52 kDa protein tryptic digest generated much
weaker signals, five of which were chosen for peptide
mass fingerprinting. Human cytokeratin 8 was fourth
 .in the list with six hits data not shown . Other
signals in the spectrum were used to confirm that this
protein was the most likely identity of the 52 kDa
band.
3.3. Cytokeratin western blotting
Affinity purified material was subjected to western
blotting using a panel of cytokeratin antibodies. A
Table 1
 .The 10 most likely matches from a search of the peptide mass database generated from the SWISS_PROT sequence database using
mass data from the 48kDa band tryptic digest spectrum
Position aHits Mol. wt. Accession Protein
 .1 7 47 928.1 K1CR_HUMAN Keratin, type I cytoskeletal cytokeratin 18
2 7 55 705.5 VL1_HPV11 Probable L1 protein
3 7 59 913.4 SCD2_SCHPO SCD2 protein
4 7 54 760.2 DNAB_BACSU Replication, initiation and membrane attachment protein
5 6 51 170.3 IFE_BRALA Non-neuronal cytoplasmic intermediate filament protein
6 6 52 917.7 MEC2_RAT Methyl-CPG-binding protein 2
7 6 50 301.4 CGS5_YEAST S-phase entry cyclin 5
8 5 38 216.1 GCH2_YEAST Probable GTP cyclohydrolase II
9 5 38 420.0 NAAB_BACSU NARAB protein

















Human cytokeratin 18 tryptic peptides identified by MALDI-MS and MassMap searching
Tryptic Experimental Theoretical Sequence
Fragment mass, MHq mass, MHq
Peptides observed in mass search
T2 976.65 976.05 STFSTNYR
T20 1040.80 1042.22 IVLQIDNAR
T24 1268.20 1268.40 QSVENDIHGLR
T24r25 1396.90 1396.54 QSVENDIHGLRK
T28r29 1040.80 1038.30 EELLFMKK
T40 1508.30 1507.72 TVQSLEIDLDSMR
T47r48 1294.00 1293.52 VKLEAEIATYR
Peptides not observed in mass search
T22r23 1241.7 1240.50 VKYETELAMR
T13r14 925.61 925.10 IREHLEK
Additional mass signals that correspond to cytokeratin 18 peptides
T24r25 685.66 684.81 KGPQVR
T21 808.29 807.89 LAADDFR
T34 966.26 966.00 AQYDELAR
T54 992.15 993.06 VVSETNDTK
T7 1094.10 1094.20 ETMQSLNDR
T4r5 1142.60 1140.30 ISVSRSTSFR
T46 1421.20 1420.60 QAQEYEALLNIK
T13r14r15r16 1590.00 1590.90 IREHLEKKGPQVR
T7r8 1912.90 1913.14 ETMQSLNDRLASYLDR
T12r13r14r15r16 2048.60 2048.40 LESKIREHLEKKGPQVR
T6 2263.90 2262.60 GGMGSGGLATGIAGGLAGMGGIQNEK
T50 2742.80 2741.96 LLEDGEDFNLGDALDSSNSMQTIQK
T49r50 2898.10 2898.10 RLLEDGEDFNLGDALDSSNSMQTIQK
T6r7 3337.40 3337.40 GGMGSGGLATGIAGGLAGMGGIQNEKETMQSLNDR
T37r38 4042.70 4045.30 EELDKYWSQQIEESTTVVTTQSAEVGAAETTLTELR
T37r38r39 4198.90 4201.50 EELDKYWSQQIEESTTVVTTQSAEVGAAETTLTELRR
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 .Fig. 2. Western blotting of affinity purified material with a panel of cytokeratin antibodies. Anti-cytokeratin 8 M20 reacts strongly with
 .both 52 and 48 kDa proteins. Anti-cytokeratin 18 CY-90 reacts strongly with the 48 kDa protein. Some cross-reactivity is seen with
 .  .anti-cytokeratin 19 K4.62 but not A53 .
pan-specific cytokeratin monoclonal antibody clone
.no. C-11, Sigma confirmed that two bands of 52 and
 .48 kDa m.w. cross-reacted strongly data not shown
indicating that these proteins could belong to the
cytokeratin family. Further blotting with more spe-
cific cytokeratin monoclonal antibodies revealed that
 .anti-cytokeratin 8 M20 apparently cross-reacted
 .strongly with both bands Fig. 2 . The lower band is
however a proteolytic degradation product that closely
co-migrates with cytokeratin 18. Anti-cytokeratin 18
 .CY-90 cross-reacted strongly with only the lower
 .48 kDa band Fig. 2 . The results obtained by mass
spectrometry and the antibody cross-reactivity match
the previously reported m.ws. of 52 kDa for cytoker-
w x w xatin 8 14 and 48 kDa for cytokeratin 18 15 . Mono-
 .  .clonal antibodies to cytokeratins 4 6B10 , 17 CKE3
 .and 19 4.62 did not cross-react with either band
although 4.62 weakly bound to the 48kDa band Fig.
.  .2 . Another anti-cytokeratin 19 A 53 monoclonal
 .antibody detected no signal Fig. 2 . The m.w. of
w xcytokeratin 19 is 40 kDa 16 and this does not corre-
spond to either of the bands shown. Cytokeratins
occur in paired form usually composed of an acidic
w xand a basic type 17,18 . Cytokeratin 8 and 18 are a
commonly occurring pair of this type in epithelial
w xcells 17 . Therefore it is likely that affinity purifica-
tion has removed both cytokeratin 8 and 18 by
co-association.
3.4. The co-association of cytokeratin 8 and lipocortin
( )1 in intermediate filament IF assembly
An enriched IF preparation isolated from A549
w xcells 9 was analysed by SDS–PAGE and following
 .staining with PAGE Blue 250 Fig. 3, lane a was
found to consist predominantly of two proteins of
m.w. 52 and 48 kDa. Several other minor bands were
co-isolated as potential Intermediate Filament-Asso-
 .ciated Proteins IFAPs including one of 37 kDa
 .arrowed . Western blotting of the PVDF transfer
 .using anti-cytokeratin 8 M20 confirmed the 52 kDa
 .band to be cytokeratin 8 Fig. 3, lane b . Several
other minor proteolytic products were present includ-
ing the 48 kDa band. Western blotting with sheep
polyclonal anti-lipocortin 1 confirmed the identity of
 .the 37 kDa band as lipocortin 1 Fig. 3, lane c .
The presence of lipocortin 1 as an IFAP in cycles
of IF assemblyrdisassembly was investigated further
w xusing well-established procedures 13,19 . IF en-
riched pellets prepared as above were dialysed at 48C
into a low salt buffer comprising of 5 mM Naq
phosphate pH 7.2, 1 mM EDTA, 1 mM PMSF for
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 .Fig. 3. A549 intermediate filament IF composition. The
polypeptide content of an enriched IF preparation analysed by
SDS–PAGE and stained with PAGE Blue 250 shows two pre-
dominant bands of 52 and 48 kDa with several other minor
 .potential IFAPs present lane a . PVDF transfer and western
 .blotting with anti-cytokeratin 8 M20 stains the 52 kDa band and
 .other minor proteolytic degradation products lane b . Western
blotting with sheep anti-lipocortin 1 stains the 37kDa band lane
.c .
18 h and clarified by centrifugation at 265 000=g
 .for 1 h. The resulting supernatant designated S1
w xconsists largely of disassembled fragments 13,19 .
Assembly was initiated by the addition of 0.09 vol-
umes of 1.9 M NaCl to the low salt buffer at room
temperature for 2 h. The assembled IFs were pelleted
by centrifugation at 157 000=g for 45 min at 238C
and designated P . The procedure was repeated to1
 .yield twice-cycled IFs S and P . Total protein2 2
equivalents of each fraction were analysed by SDS–
PAGE and following staining with PAGE Blue 250
the presence of the 52 and 48 kDa bands was con-
firmed throughout the complete cycle of IF assem-
  ..blyrdisassembly Fig. 4 A . Furthermore, following
PVDF transfer, western blotting with the sheep anti-
lipocortin 1 confirmed the presence of lipocortin 1
  ..throughout the IF assembly cycle also Fig. 4 B .
The presence of lipocortin 1 is maintained in EDTA-
containing buffer thus again confirming the calcium-
independence of this association. Furthermore, blot-
ting of cytokeratin immunoprecipitates with antisera
to annexin 2 and annexin 5 failed to demonstrate the
 .presence of these proteins data not shown . This
again serves to confirm that the interaction between
Fig. 4. Association of lipocortin 1 in disassembly and assembly cycling of A549 IFs. IF peparations were dialysed into low salt buffer,
 .clarified by centrifugation and the supernatant designated S . Addition of NaCl initiated IF assembly which was pelleted P . The1 1
procedure was repeated to yield twice-cycled IFs S and P . Total protein equivalents analysed by SDS–PAGE and stained with PAGE2 2
 .Blue 250 show the presence of the 52 and 48 kDa bands throughout IF assembly cycle A . Transfer to PVDF and western blotting with
 .sheep anti-lipocortin 1 shows that lipocortin 1 is not disassociated during this cycle B .
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lipocortin 1 and cytokeratin 8 is specific and is not a
general feature of annexin–cytokeratin association.
3.5. Immunofluoresence e˝idence for a subcellular
localization between lipocortin 1 and cytokeratin 8
In Fig. 5 the subcellular localization of lipocortin 1
and cytokeratin 8 in A549 cells is shown with dou-
ble-labelling immunofluoresence microscopy using
 .mouse monoclonal anti-cytokeratin 8 A, C and E
 .and sheep anti-lipocortin 1 B, D and F antibodies.
These antibodies demonstrated the existence of a
very close morphological distribution between the
respective antigens in all the physiological states
studied. In well spread cells both antibodies revealed
the typical cytokeratin intermediate filament network
  ..throughout the cytoplasm Fig. 5 A and B . Both
antigens also co-localized in cell–cell contact areas
where lipocortin 1 appeared together with cytokeratin
bundles which are normally associated with desmo-
  ..somes Fig. 5 C and D . The co-localization of
lipocortin 1 and cytokeratin 8 is most evident in
  ..mitotic cells Fig. 5 E and F . The persistence of the
co-distribution of lipocortin 1 and cytokeratin 8 in
 .Fig. 5. Double label immunofluoresence localization of cytokeratin 8 and lipocortin 1 in A549 cells. A, C and E show the monoclonal
 .mouse anti-cytokeratin 8 staining patterns. B, D, and F show the sheep anti-lipocortin 1 staining patterns. The two distribution patterns
 .are very similar. Well spread A549 cells show co-localization of lipocortin 1 and cytokeratin 8 throughout the cytoplasm A and B .
 .Co-localization with cytokeratin IF bundle-associated desmosomes is also seen between the contact areas of two adjacent cells C and D .
The association of these two antigens is most obvious in mitotic cells which are shown in E and F. Magnification 690= .
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A549 cells throughout the mitotic cycle is very simi-
lar to that of the co-association between a 300 kDa
w xprotein and IFs reported previously 19 .
4. Discussion
Several members from the annexin family of pro-
teins are known to associate with a variety of cyto-
skeletal structures such as actin, spectrin, tropomyosin
w xand calspectrin 20–23 and perhaps more impor-
tantly to bind both phospholipid and actin in a Ca2q-
w xdependent manner 20 . However, the role of this
association in determining the biological effects of
the annexins is unknown. The cytoskeleton was once
thought of only in terms of maintaining the structural
integrity of the cell. However, cytoskeletal disruptive
w xdrugs have anti-inflammatory 24 and anti-prolifera-
w xtive properties 25–27 , and it is now apparent that it
plays a far more dynamic role in processes such as
cell signalling, secretion and division.
The cytoskeleton is composed of several kinds of
proteins which include actin filaments, microtubules
 .and intermediate filaments IFs . IF proteins are de-
rived from a large multigene family and although
their expression is highly regulated a functional role
is still unclear. The cytokeratins make up the largest
group within the IF family and are composed of two
w xsub-families, an acidic type I and a basic type II 15 .
Separately, each type is highly insoluble, and there-
fore they are usually expressed as a hetero-tetramer
w xcomposed of two type I and two type II proteins 15 .
Cytokeratin filaments typically form specific pairs
and cytokeratin 8 is frequently associated with cytok-
eratin 18 which together form a more stable complex
w xfor filament formation 17,18 . The expression of
cytokeratins 8 and 18 in hepatocytes has been shown
w xto be regulated by glucocorticoids 28 . How this
could mediate actions of steroids is not yet clear,
particularly in respect to the regulation of cell growth.
However, it may be significant that cytokeratin 8 is
w xoften over-expressed in metastatic cells 29,30 and
the transfection of complete keratin filaments into
mouse L cells augments cell migration and invasion
w x31 . Again the functional role of cytokeratins in
these processes is not clear. However, the develop-
ment of a keratin 8-deficient mouse may help to shed
more light as already this animal has shown an
increased susceptibility to inflammation and colorec-
w xtal hyperplasia 32 .
In an attempt to further evaluate the role of IFs at a
cellular level the interaction of signalling mediators
with specific components of the cytoskeleton is cur-
rently under investigation in a number of systems.
For example, profilin plays an important role in actin
polymerization by regulating phosphoinositide hydro-
w xlysis 33 . More recently, G protein b and g subunits
have been shown to associate not only with the
plasma membrane but also with cytokeratin filaments
w xof the cytoskeleton in starfish oocytes 34 . Further-
more, phosphorylation of cytokeratin 18 has been
implicated in filament reorganization at interphase
w x35 and in A549 cells activation of the uPA receptor
results in phosphorylation of cytokeratin 8 with which
w xit is associated 36 . Similarly, amino- and carboxyl-
terminal end phosphorylation of cytokeratin 8 by
cAMP-dependent protein kinase induces disassembly
w xof the keratin filament structure 37 .
The role of cytoskeletal elements in cell signalling
is now becoming more apparent. For example, the
catalytic capacity of EGF receptor transfected into
mouse fibroblasts is facilitated by the cytoskeleton
w x38 . EGF treatment of A431 cells promotes the
association of PLC with the EGF receptor and actin
w xwithin an area of membrane ruffling 39 . Similarly,
PLC, DAG kinase and pp60 all associate with the
platelet cytoskeleton following activation by throm-
w xbin 40 and c-Src translocates to the glioblastoma
cytoskeleton following activation by EGF and PDGF
w x41 . The fMLP receptor complex also associates with
the neutrophil cytoskeleton in G protein-dependent
w xmanner 42 . These results indicate that the integrity
of the cytoskeleton plays an important role in mediat-
ing or facilitating cell signalling events. G protein
activation by growth factor receptors is mediated by
the recruitment of adaptor proteins to the signalling
cascade. One such adaptor protein is Grb2 which
w xmediates the activation of ras by EGF receptor 43 .
The role of the cytoskeleton in this phenomenon is
reinforced by the fact that Grb2 is recruited to the
membranercytoskeleton interface following EGF ac-
w xtivation of several cell systems 44 .
In A549 cells EGF stimulates cPLA activity and2
thus the release of arachidonic acid by a G protein
w xdependent mechanism 9,10 . This process is inhib-
ited by an N-terminal peptide fragment, Lc13–25
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 . w xbut not Lc1–12 , of lipocortin 1 9,10 . We now
 .report that Lc13–25 but not Lc1–12 binds selec-
tively to cytokeratin 8 and that lipocortin 1 and
cytokeratin 8 co-localize within A549 cells. This
association is apparently Ca2q-independent and is
thus distinguished from the Ca2q-dependent binding
of phospholipid to the core domain. The interaction
of lipocortin 1 with specific elements within the
cytoskeleton through its N-terminal domain may play
an important role in regulating G protein dependent
activation of cPLA and other cellular events. Re-2
cently, the association of lipocortin 1 with endosomes
was shown to require an intact N-terminal domain
w x45 . More specifically, the removal of the first 13
N-terminal residues did not affect this association. In
other words the domain of interaction was contained
within the fragment Lc13–25 which we have identi-
fied as having cytokeratin binding properties and to
be bioactive.
Details of the association of members of the an-
nexin family with the cytoskeleton are now becoming
more clear. Lipocortin 1 stains heavily in the basal
keratinocytes of human skin and appears to be associ-
w xated with cytoskeletal elements 46 . Lipocortin 2
co-localizes with actin and keratin in fibroblasts and
keratinocytes where it may stabilize filament bundling
w x47 . These interactions may be direct or mediated via
other proteins. For instance, the association of
lipocortin 2 with the cytoskeleton of MDCK cells is
dependent on the presence of p11—a member of the
w xS100 family of proteins 48 . Recently another of the
S100 proteins was found to bind the cytoskeleton and
w xlipocortin I 49 and the direct association of lipocortin
1 with S100C has been shown to mediated via a
w xdomain within peptides 1–18 of the N-terminus 50 .
Although this domain apparently binds to neither
cytokeratin 8r18 nor endosomes, this nevertheless
leaves an intriguing possibility of a bi-functional
domain within the first 26 residues of the N-terminus
of lipocortin 1 which binds an S100 component and a
cytokeratin component.
The structure of proteins from the annexin family
follows a common pattern with each protein having a
2q w x4 unit repeat Ca -phospholipid binding domain 3 .
The proteins are distinguished from one another by
w xunique N-termini of varying lengths 3 . The common
core domain has been considered as the major func-
tional moiety of annexins presumably because of its
ability to bind and sequester phospholipid in a Ca2q-
w xdependent manner 5 . However, we and others have
shown that short peptide fragments derived from the
N-terminal domain which do not bind phospholipid
mimic many of the properties of the parent protein. In
particular, we have shown in A549 cells that Lc13–25
inhibits cell growth, PGE release and arachidonic2
w xacid release 8,9 . Furthermore, the G protein-depen-
dent activation of arachidonic acid release is inhibited
by dexamethasone in a lipocortin 1-dependent man-
w xner 9 . The peptide Lc13–25 similarly inhibits this
w xprocess 9 . We now show here that it is this N-termi-
nal portion of lipocortin 1 that specifically interacts
with components of the cytoskeleton.
The co-localization of lipocortin 1 and cytokeratin
8 in intact A549 cells was confirmed by double-label-
 .ling immunofluoresence Fig. 5 . The distribution
patterns were essentially co-incident throughout the
cytoplasmic keratin network. Furthermore, co-locali-
zation was also seen with the keratin bundles that are
associated with desmosomes between the contact ar-
eas of two adjacent cells. The association of lipocortin
1 and cytokeratin 8 was however, most obvious in
 .dividing cells Fig. 5, E and F
The isolation of separate forms of cytokeratin 8
and 18 by the Lc13–25 affinity matrix perhaps seems
unlikely due to the highly insoluble nature of these
proteins. Rather, it would appear that Lc13–25 inter-
acts with just cytokeratin 8 and that cytokeratin 18 is
isolated by co-association as a pair or even in a
tetrameric complex form which is then separated
under the denaturing conditions of SDS–PAGE. The
125   .binding of I-Lc13–25 to both bands Fig. 1 C
apparently indicates that the peptide interacts with
both cytokeratin 8 and 18. However, there is little
homology between these proteins so this also seems
unlikely. It is more likely that the peptide interacts
with the truncated form of cytokeratin 8 instead. The
close localization of lipocortin 1 and cytokeratin 8 as
components of IFs in A549 cells is confirmed in Fig.
.4 . Most significantly, this association persists
throughout cycles of IF assembly and disassembly
indicating that lipocortin 1 binds both soluble and
insoluble forms of cytokeratin and therefore can be
classified as an IFAP. This feature is apparently
similar to that reported for a 300 kDa protein associ-
w xated with IFs 19 but distinguished from that of other
low m.w. IFAPs which become disassociated during
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w xthe IF cycling procedure 13 . The association of
lipocortin 1 and cytokeratin 8 also persists in the
absence of Ca2q again confirming the Ca2q-indepen-
dence of this phenomenon. The abundance of
lipocortin 1 is apparently low but again this is similar
to that reported for the 300 kDa protein which repre-
w xsents approximately 3% of IFAP 19 . The portion of
total cellular lipocortin 1 this represents is not known,
but since this is the pool in which glucocorticoid-in-
w xduced lipocortin 1 appears 11 it may represent the
biologically active pool.
Recently, truncated soluble forms of cytokeratin 8
released into the culture media of breast cancer cell
w xlines cells have been identified 51 . These forms of
cytokeratin have the ability to bind plasminogen and
w xtissue-type plasminogen activator 51 . More signifi-
cantly, an extracellular epitope of cytokeratin 8 ex-
pressed in both hepatocytes and breast cancer cells
has been shown to mediate the binding of plasmino-
w xgen to the surface of these cells 29,52 . This raises
the exciting possibility of the existence of a common,
cell surface binding site to both lipocortin 1 and
plasminogen which may account for the saturable
binding properties of lipocortin 1 previously de-
w xscribed 6,7 .
The close association of lipocortin 1 and cytoker-
atin 8 seen in A549 cells would imply a functional
relationship between these proteins and the fact that
Lc13–25 selectively binds cytokeratin 8 could pro-
vide one clue to the mechanism for the inhibitory
actions of this peptide.
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